News Feature: FDA Panel Rejects Tanezumab for Osteoarthritis A 2 day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab for use in OA. https://t.co/ltKmm9Nl1y https://t.co/qTWhSX9LBd